Marksans Pharma Ltd Share Price

Pharmaceuticals - Indian - FormulationsNSE
₹291.15
-7.90-2.64% (1D)
As on 20 Nov 2026 at 15:59
As of 20 Nov 2026 at 15:59, Marksans Pharma Ltd is trading at ₹291.15. The 52-week range stands at ₹155.00–₹350.95, with a market cap of ₹13.18 thousand crore. At a P/E of 42.91 and a dividend yield of 0.31%, it is a mid-cap stock in the Pharmaceuticals sector.

MARKSANS Price Chart

Market Cap
₹13.18K Cr
PE Ratio
42.91
ROCE
22.35%

Marksans Pharma Ltd Performance

Marksans Pharma Ltd Fundamentals

Know More
Market Cap₹13.18K Cr
ROE17.35%
P/E Ratio (TTM)42.91
EPS (TTM)₹6.78
P/B Ratio7.44
Dividend Yield0.31%
Industry P/E91.72
Book Value₹39.10
Debt to Equity0.01
Face Value₹1

Marksans Pharma Ltd Shareholding Pattern

Know More
Promoter43.9%
Foreign Institutions19.1%
Mutual Funds3.7%
Domestic Institutions1.8%
Public31.5%

Marksans Pharma Ltd Financial Statements

Know More
No data for this view.

Marksans Pharma Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Marksans Pharma

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited, pursuant to High Court order dated 19th August, 2005. The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015. The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. Access Healthcare for Medical Products LLC, a Dubai-based front-marketing and promotion company was acquired in June, 2022. In 2023-24, Company acquired the business unit of Tevapharm India Private Limited in Verna, Goa as a going concern via slump sale in April, 2023. During the year 2026, the Company has incorporated two wholly owned subsidiaries viz., Marksans (Canada) Inc. in Canada and Marksans Pharma (Europe) Limited in Ireland. Secondly, the Company entered Germany, Canada and Ireland markets and launched Nova Pharma's branded prescription business in Australia and New Zealand.

Parent Organisation—
Founded1992
Managing DirectorMark Saldanha
NSE SymbolMARKSANS

Marksans Pharma Ltd Resistance and Support levels

R3305.85R2302.28R1300.07S1292.93S2290.72S3287.15291.15

Marksans Pharma Ltd Technicals

Current Price
₹291.15 ₹7.90 (-2.64%)
Bearish
10
Bullish
2
  • 20 Day5.3%
  • 50 Day5.6%
  • 100 Day1.3%
  • 200 Day8.3%

Marksans Pharma Ltd Latest News

View More
04 NOV 2026 | Wednesday
Marksans Pharma approves allotment of shares to employees under stock option scheme
19 OCT 2026 | Monday
Marksans Pharma to review financial results at a board meeting November 4, 2026
13 OCT 2026 | Tuesday
Marksans Pharma submitted a regulatory certificate to the BSE and NSE exchanges
25 SEPT 2026 | Friday
Marksans Pharma restricts trading for insiders ahead of September 2026 financial results
04 AUG 2026 | Tuesday
Marksans Pharma prioritizes quality, ethical practices, and community engagement in its operations
31 JUL 2026 | Friday
Marksans Pharma to review quarterly results at a Mumbai board meeting on August 12
22 JUL 2026 | Wednesday
Marksans Pharma Ltd Falls 5.24%, BSE Healthcare index Drops 1.34%
21 JUL 2026 | Tuesday
Marksans Pharma completes acquisition of ABCnow GmbH
08 JUL 2026 | Wednesday
Marksans Pharma inks deal to acquire ABCnow GmbH
08 JUL 2026 | Wednesday
Marksans Pharma rises after acquiring 100% stake in ABCnow GmbH

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Marksans Pharma Ltd is ₹291.15 as of 20 Nov 2026 at 15:59.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now